The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

An international team of researchers, led by the University of Glasgow, hopes to find new ways to target opioid addiction ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and changes in bowel habits, including diarrhea, ...

DOTHAN, Ala. (WTVY) - The Southeast Health Foundation is expanding its HeartSafe initiative. HeartSafe focuses on reducing ...

Background: Fentanyl, a short-acting synthetic opioid, has a pharmacokinetic ... to rescue medication were also recorded. Results: The pharmacokinetics of intravenous fentanyl reflected a 2 ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and ...

Antidotes are critical in toxicology, offering therapeutic solutions to poisoning by neutralizing toxins and enhancing the ...

The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological ...

Hosted by the Tulane University Center for Continuing Education, seminar brings together leading researchers and clinicians ...